- A new Bloomberg Intelligence investor survey revealed which biotechs are most likely to be bought in 2021.
- Alexion Pharmaceuticals, Blueprint Medicines, Neurocrine, Trillium Therapeutics, and Global Blood Therapeutics rank among the top takeout targets highlighted by investors.
- The survey had the 78 anonymous respondents identify the top takeout targets for five major drug industry leaders: Pfizer, Sanofi, Biogen, Gilead, and Vertex.
The biotech industry is anticipating another bustling year in 2021, and a new Bloomberg Intelligence survey of investors reveals some of the hottest takeout targets headed into the new year.
Word abonnee van Business Insider